Sol-Gel Technologies (Sol-Gel Technologies) Short-Term Debt : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Sol-Gel Technologies Short-Term Debt?

Sol-Gel Technologies's Short-Term Debt for the quarter that ended in Dec. 2023 was $0.00 Mil.

Sol-Gel Technologies Short-Term Debt Historical Data

The historical data trend for Sol-Gel Technologies's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sol-Gel Technologies Short-Term Debt Chart

Sol-Gel Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

Sol-Gel Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Sol-Gel Technologies Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sol-Gel Technologies Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Sol-Gel Technologies's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sol-Gel Technologies (Sol-Gel Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sol-Gel Technologies Ltd (NAS:SLGL) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

4SG:Germany 4SG:Germany

Address

7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650

Website

https://www.sol-gel.com

Sol-Gel Technologies Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.